Last Updated: 30 September 2026
Retatrutide is the name on everyone’s lips in the weight loss world. The experimental injection from Eli Lilly has posted some of the most dramatic trial results ever seen for an obesity drug — and patients, doctors and investors are all watching closely. But what actually is retatrutide, how does it work, and when could it reach patients in the UK? In this guide we break down seven powerful facts: the triple-action science, the headline trial numbers, how it compares with Mounjaro and Wegovy, the side effects, and what UK regulators have said so far. Important: this article is for information only and is not medical advice — always speak to your GP or pharmacist about weight management.
What is retatrutide? Retatrutide is an investigational once-weekly injection developed by Eli Lilly that targets three hormone receptors — GLP-1, GIP and glucagon — to reduce appetite and aid weight loss. In phase 2 trials, participants lost up to 24% of body weight. It is not yet approved for general use in the UK.
What Is Retatrutide? The Triple-Action Science Explained
Retatrutide (research code LY3437943) is a weekly injectable drug being developed by the pharmaceutical company Eli Lilly for obesity and type 2 diabetes. What makes it different is its triple mechanism: it mimics three gut hormones at once.
- GLP-1 — the same pathway used by semaglutide (Wegovy/Ozempic); slows digestion and reduces appetite.
- GIP — also targeted by tirzepatide (Mounjaro); improves insulin response and further curbs hunger.
- Glucagon — the novel addition; raises energy expenditure so the body burns more calories at rest.
No approved weight loss drug currently hits all three receptors. That triple action is why researchers — and the media — have dubbed retatrutide the potential “triple G” or next-generation obesity treatment.
The drug is given as a once-weekly injection under the skin, using a pre-filled pen similar to those used for Mounjaro and Wegovy.
Retatrutide Trial Results: The Headline Numbers
The results that made retatrutide famous came from a phase 2 trial published in the New England Journal of Medicine. Adults with obesity who took the highest dose lost an average of 24.2% of their body weight after 48 weeks.
To put that in context: a person weighing 110kg could lose more than 26kg on that trajectory. Roughly a quarter of participants lost 30% or more of their starting weight — figures previously seen only with bariatric surgery.
| Drug | Average weight loss (trial) | Mechanism |
|---|---|---|
| Retatrutide (12mg) | ~24% | GLP-1 + GIP + glucagon |
| Tirzepatide / Mounjaro | ~21% | GLP-1 + GIP |
| Semaglutide / Wegovy | ~15% | GLP-1 |
Phase 3 trials — the large final-stage studies regulators require before approval — have been recruiting through 2025 and 2026. Full results are expected to read out before any licensing decision.
Retatrutide vs Mounjaro vs Wegovy: How They Compare
Patients often ask how retatrutide stacks up against the injections they can already get. The honest answer: the trial numbers look better, but the drugs have never been compared head-to-head.
Mounjaro (tirzepatide), also from Lilly, is a dual GLP-1/GIP drug averaging around 21% weight loss at its top dose. Wegovy (semaglutide) from Novo Nordisk averages about 15%. Retatrutide’s triple mechanism adds glucagon-driven calorie burning on top.
There are trade-offs. The glucagon component may increase heart rate and nausea, and retatrutide’s long-term safety data is far thinner than its rivals’. Until phase 3 data and regulatory reviews are complete, Mounjaro and Wegovy remain the proven options.
Retatrutide Side Effects: What the Trials Showed
Like all GLP-1-based drugs, retatrutide causes gastrointestinal side effects in many users. In trials the most common were:
- Nausea and vomiting, especially when starting or increasing the dose
- Diarrhoea or constipation
- Reduced appetite (the intended effect, but it can be intense)
- Increases in heart rate, linked to the glucagon component
- Skin sensitivity changes reported by some participants
Most side effects were rated mild to moderate and faded with time. But serious risks seen across this drug class — including pancreatitis and gallbladder problems — mean retatrutide will only ever be a prescription medicine taken under medical supervision.
Anyone considering a weight loss injection should discuss the full risk profile with their GP. Buying unlicensed “retatrutide” from online sellers is dangerous — counterfeit pens may contain unknown substances.
Is Retatrutide Available in the UK? Approval Status
As of 30 September 2026, retatrutide is not approved for general use in the UK. It remains an investigational medicine available only inside clinical trials.
For UK patients, the licensed options remain Wegovy (semaglutide) on the NHS for eligible patients and via private prescription, and Mounjaro (tirzepatide), which has been rolling out through NHS weight-management services and private clinics.
Eli Lilly has signalled it will seek regulatory approval once phase 3 results are in, with submissions to the US FDA and the UK’s MHRA expected to follow. Analysts speculate a launch could come in 2027 or 2028 if the data holds up — but that is not guaranteed.
7 Powerful Facts About Retatrutide at a Glance
- Triple action: the first obesity drug candidate to target GLP-1, GIP and glucagon together.
- ~24% weight loss: the highest average reduction seen in a phase 2 obesity drug trial.
- Once weekly: a single under-the-skin injection using a pre-filled pen.
- Made by Lilly: developed by Eli Lilly, the company behind Mounjaro.
- Not yet approved: still investigational; not available on prescription in the UK.
- Side effects: mainly nausea, vomiting and digestive issues, plus heart-rate increases.
- Watch 2027–28: phase 3 results will decide whether regulators license it.
Should You Wait for Retatrutide? A Balanced View
The retatrutide hype is understandable — the numbers are extraordinary. But obesity specialists urge caution: trial volunteers are closely monitored, doses are titrated carefully, and real-world results are almost always more modest.
There is also the question of staying power. Weight regain after stopping GLP-1 drugs is well documented, and retatrutide is likely to be a long-term or lifelong therapy for most users — with long-term costs and unknown decades-long effects.
The sensible path for anyone struggling with weight today: speak to your GP about the proven options already available, from NHS weight-management programmes to licensed medicines like Wegovy and Mounjaro. Do not wait years for a drug that may or may not arrive — and never buy unlicensed injections online.
What is retatrutide?
Retatrutide is an investigational once-weekly weight loss injection developed by Eli Lilly. It targets three hormone receptors — GLP-1, GIP and glucagon — to reduce appetite and increase calorie burning. It is not yet approved for general use.
How much weight can you lose on retatrutide?
In a phase 2 trial, participants on the highest dose lost an average of 24.2% of body weight over 48 weeks, with around a quarter losing 30% or more. Real-world results may differ, and phase 3 data is still pending.
Is retatrutide available in the UK?
No. As of September 2026, retatrutide is not approved in the UK and is only available inside clinical trials. Licensed alternatives include Wegovy and Mounjaro, available via the NHS for eligible patients and privately.
What are the side effects of retatrutide?
Trial participants most commonly reported nausea, vomiting, diarrhoea and constipation, plus increases in heart rate linked to the glucagon component. Serious class-wide risks include pancreatitis and gallbladder problems.
Is retatrutide better than Mounjaro?
Retatrutide’s trial weight loss (~24%) beats Mounjaro’s (~21%), but the two have never been compared head-to-head, and retatrutide’s long-term safety data is much thinner. Mounjaro is the proven, licensed option today.
When will retatrutide be approved?
There is no confirmed date. Phase 3 trial results are expected first, with regulatory submissions possibly following in 2027. Approval would then depend on the MHRA (UK) and FDA (US) reviews.
Final Thoughts
Retatrutide may be the most exciting obesity drug ever tested — but it is still a medicine of the future, not the present. The science is genuinely novel, the numbers are remarkable, and the next two years will decide whether it changes weight care forever.
For more health news and evidence-based guides, follow FamePost — and always talk to your GP before starting any weight loss treatment.
Disclaimer: This article is for general information only and is not medical advice. Always consult a qualified healthcare professional about weight management or prescription medicines.
